BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1690288)

  • 1. Progress in vaccine development against SIV and HIV.
    Bolognesi DP
    J Acquir Immune Defic Syndr (1988); 1990; 3(4):390-4. PubMed ID: 1690288
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccination against HIV and SIV.
    Leclerc C
    Curr Opin Immunol; 1989-1990 Feb; 2(3):428-32. PubMed ID: 2483885
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccination against SIV infection and disease.
    Gardner MB
    AIDS Res Hum Retroviruses; 1990 Jul; 6(7):835-46. PubMed ID: 2167709
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of simian immunodeficiency virus for evaluation of AIDS vaccine strategies.
    Daniel MD; Desrosiers RC
    AIDS; 1989; 3 Suppl 1():S131-3. PubMed ID: 2558686
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative approach to retroviral vaccines.
    Burny A
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):389-92. PubMed ID: 8882316
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical AIDS vaccine development: formal survey of global HIV, SIV, and SHIV in vivo challenge studies in vaccinated nonhuman primates.
    Warren JT; Levinson MA
    J Med Primatol; 1997; 26(1-2):63-81. PubMed ID: 9271191
    [No Abstract]   [Full Text] [Related]  

  • 7. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies.
    Warren JT; Dolatshahi M
    J Med Primatol; 1993; 22(2-3):203-35. PubMed ID: 8411110
    [No Abstract]   [Full Text] [Related]  

  • 8. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2.
    Biberfeld G; Thorstensson R; Putkonen P
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):443-6. PubMed ID: 8882330
    [No Abstract]   [Full Text] [Related]  

  • 9. DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.
    Hu X; Valentin A; Dayton F; Kulkarni V; Alicea C; Rosati M; Chowdhury B; Gautam R; Broderick KE; Sardesai NY; Martin MA; Mullins JI; Pavlakis GN; Felber BK
    J Immunol; 2016 Nov; 197(10):3999-4013. PubMed ID: 27733554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies.
    O'Connor DH; Allen TM; Watkins DI
    DNA Cell Biol; 2002 Sep; 21(9):659-64. PubMed ID: 12396608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AIDS preclinical vaccine development: biennial survey of HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates.
    Warren JT; Levinson MA
    J Med Primatol; 1999; 28(4-5):249-73. PubMed ID: 10593492
    [No Abstract]   [Full Text] [Related]  

  • 12. AIDS vaccine study reported.
    Am Fam Physician; 1990 Feb; 41(2):684, 686. PubMed ID: 2154084
    [No Abstract]   [Full Text] [Related]  

  • 13. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents.
    Gardner MB
    Antiviral Res; 1991 May; 15(4):267-86. PubMed ID: 1659310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.
    Roff SR; Sanou MP; Rathore MH; Levy JA; Yamamoto JK
    Hum Vaccin Immunother; 2015; 11(6):1540-56. PubMed ID: 25844718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology and immunopathology of simian immunodeficiency virus infection.
    Fultz PN; Anderson DC
    Curr Opin Immunol; 1989-1990 Feb; 2(3):403-8. PubMed ID: 2561344
    [No Abstract]   [Full Text] [Related]  

  • 17. Cellular and molecular mechanisms of vaccine-induced protection against retroviral infections.
    Dittmer U; Hasenkrug KJ
    Curr Mol Med; 2001 Sep; 1(4):431-6. PubMed ID: 11899087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.
    Munson P; Liu Y; Bratt D; Fuller JT; Hu X; Pavlakis GN; Felber BK; Mullins JI; Fuller DH
    Hum Vaccin Immunother; 2018 Jul; 14(7):1820-1831. PubMed ID: 29648490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postexposure immunotherapy of simian immunodeficiency virus (SIV) infected rhesus with an SIV immunogen.
    Gardner MB; Jennings M; Carlson JR; Lerche N; McGraw T; Luciw P; Marx P; Pedersen N
    J Med Primatol; 1989; 18(3-4):321-8. PubMed ID: 2547966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.